Randomized phase 3 study of anthracycline-containing regimens versus S-1 as first-line treatment for metastatic breast cancer (SELECT BC-CONFIRM)-A combined analysis of two randomized phase 3 studies (SELECT BC-CONFIRM and SELECT BC)-

被引：0
|
作者：
Park, Y.
Akabane, H.
Watanabe, T.
Takahashi, M.
Sagara, Y.
Nishimura, R.
Tsurutani, J.
Takashima, T.
Fujisawa, T.
Hozumi, Y.
Uemura, Y.
Mukai, H.
机构：
[1] Tohoku Med & Pharmaceut Univ, Fac Med, Sendai, Miyagi, Japan
[2] Hokkaido PWFAC Asahikawa Kosei Gen Hosp, Asahikawa, Hokkaido, Japan
[3] Sendai Med Ctr, Natl Hosp Org, Sendai, Miyagi, Japan
[4] Natl Hosp Org Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Hakuaikai Med Corp Sagara Hosp, Kagoshima, Japan
[6] Kumamoto Shinto Gen Hosp, Kumamoto, Japan
[7] Kindai Univ, Fac Med, Osakasayama, Japan
[8] Osaka City Univ, Grad Sch Med, Osaka, Japan
[9] Gunma Prefectural Canc Ctr, Ota, Japan
[10] Univ Tsukuba Hosp, Ibaraki Prefectural Cent Hosp, Kasama, Ibaraki, Japan
[11] Univ Tokyo Hosp, Tokyo, Japan
[12] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P1-14-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-14-07
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer
    Higuchi, Katsuhiko
    Koizumi, Wasaburo
    Yamada, Yasuhide
    Nishikawa, Kazuhiro
    Gotoh, Masahiro
    Fuse, Nozomu
    Sugimoto, Naotoshi
    Nishina, Tomohiro
    Amagai, Kenji
    Chin, Keisho
    Niwa, Yasumasa
    Negoro, Yuji
    Imamura, Hiroshi
    Tsuda, Masahiro
    Yasui, Hirotumi
    Fujii, Hirofumi
    Yamaguchi, Kensei
    Yasui, Hisateru
    Hamada, Chikuma
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [22] A randomized multicenter phase II trial of capecitabine versus S-1 as first-line treatment in unresectable or recurrent breast cancer patients
    Yamamoto, D.
    Iwase, S.
    Odagiri, H.
    Kuroda, Y.
    Akazawa, K.
    Kitamura, K.
    Kawaguchi, T.
    Yamamoto, C.
    Nagumo, Y.
    Sakata, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] LONG-TERM EQ-5D SCORE FOR PATIENTS WITH METASTATIC BREAST CANCER; COMPARISON OF FIRST-LINE ORAL S-1 AND TAXANE THERAPIES IN THE RANDOMIZED "SELECT" TRIAL
    Fukuda, T.
    Shiroiwa, T.
    Shimozuma, K.
    Mouri, M.
    Doihara, H.
    Akabane, H.
    Kashiwaba, M.
    Watanabe, T.
    Hagiwara, Y.
    Ohashi, Y.
    Mukai, H.
    VALUE IN HEALTH, 2015, 18 (07) : A467 - A467
  • [24] Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group
    Kwakman, Johannes J. M.
    van Werkhoven, Erik
    Simkens, Lieke H. J.
    van Rooijen, Johan M.
    van de Wouw, Yes A. J.
    ten Tije, Albert J.
    Creemers, Geert-Jan M.
    Hendriks, Mathijs P.
    Los, Maartje
    van Alphen, Robbert J.
    Polee, Marco B.
    Muller, Erik W.
    van der Velden, Ankie M. T.
    van Voorthuizen, Theo
    Koopman, Miriam
    Mol, Linda
    Punt, Cornelis J. A.
    CLINICAL COLORECTAL CANCER, 2019, 18 (02) : E229 - E230
  • [25] A multicenter randomized phase III study of albumin-bound paclitaxel combined with S-1 (AS) versus oxaliplatin combined with S-1 (SOX) for first-line treatment of advanced gastric cancer (GAPSO study)
    Dai, Yuhong
    Yu, Xiongjie
    Xu, Huiting
    Zhuang, Liang
    Zhang, Mingsheng
    Zou, Yanmei
    Fu, Qiang
    Qiu, Hong
    Yuan, Xianglin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
  • [27] Combined analysis of three randomized phase III trials comparing S-1 monotherapy and S-1 combination therapy for first-line treatment of advanced gastric cancer.
    Takeuchi, Madoka
    Ichikawa, Wataru
    Shitara, Kohei
    Sunakawa, Yu
    Oba, Koji
    Michimae, Hirofumi
    Saad, Everardo D.
    Koizumi, Wasaburo
    Sakata, Yuh
    Furukawa, Hiroshi
    Buyse, Marc E.
    Takeuchi, Masahiro
    Fujii, Masashi
    Nakajima, Toshifusa
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [28] Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
    Kwakman, J. J.
    Van Werkhoven, E.
    Simkens, L. H.
    van Rooijen, J. M.
    van de Wouw, A.
    Ten Tije, A. J.
    Creemers, G-J.
    Hendriks, M. P.
    Los, M.
    van Alphen, R.
    Polee, M. B.
    Muller, E. W.
    Van der Velden, A.
    Van Voorthuizen, T.
    Koopman, M.
    Mol, L.
    Punt, C. J. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Clinical effects of prior anthracycline or taxane use on eribulin as first-line treatment for HER plus /- locally recurrent or metastatic breast cancer (BC): Results from two phase II, multicenter, single-arm studies.
    Gluck, Stefan
    O'Shaughnessy, Joyce
    McIntyre, Kristi
    Schwartzberg, Lee Steven
    Wilks, Sharon
    Puhalla, Shannon
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer
    Wang, Biyun
    Sun, Tao
    Zhao, Yannan
    Wang, Shusen
    Zhang, Jian
    Wang, Zhonghua
    Teng, Yue-E
    Cai, Li
    Yan, Min
    Wang, Xiaojia
    Jiang, Zefei
    Pan, Yueyin
    Luo, Jianfeng
    Shao, Zhimin
    Wu, Jiong
    Guo, Xiaomao
    Hu, Xichun
    NATURE COMMUNICATIONS, 2022, 13 (01)
12345